ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2459

Improvement In Physical Function, Health-Related Quality Of Life, and Work Productivity With Adalimumab Treatment In Non-Radiographic Axial Spondyloarthritis

Désirée M. van Der Heijde1, Philip J. Mease2, Aileen L. Pangan3, Sumati A Rao3, Naijun Chen3 and Mary Cifaldi3, 1Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 3AbbVie Inc., North Chicago, IL

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Health Assessment Questionnaire, patient outcomes, Questionnaires and spondylarthropathy

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Adalimumab (ADA) was approved in the European Union for  the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation (elevated C-reactive protein (CRP) or positive MRI) and inadequate response or intolerance to NSAIDs. We aimed to evaluate effects of long-term ADA treatment on patient-reported outcomes (PROs) and work productivity in nr-axSpA patients with elevated CRP or positive MRI.

Methods: ABILITY-1 is an ongoing Phase III, multicenter, randomized, controlled trial of ADA vs. placebo (PBO) in patients with nr-axSpA (fulfilling Assessment of Spondyloarthritis international Society axial SpA criteria but not modified New York criteria for ankylosing spondylitis). After the 12-week double-blind phase, all patients switched to open-label ADA (represented as ADA/ADA and PBO/ADA groups) for 144 weeks. This post-hoc analysis evaluated productivity and PROs until Week 52 among 142 patients with elevated CRP or MRI evidence of inflammation (spine or SI joints) at baseline. Physical function was assessed using the disability index of the Health Assessment Questionnaire for Spondyloarthropathies (HAQ-S) and health-related quality of life using the Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) score. Productivity was assessed using the Work Productivity and Activity Impairment Questionnaire (WPAI). Changes from baseline to Week 12 were compared between groups using ANCOVA with adjustment for baseline scores and with treatment as a factor.

Results: No significant differences between treatment groups were observed in baseline HAQ-S, SF-36 PCS, or WPAI domain scores. After 12 weeks of therapy in the double-blind period, the ADA group experienced significant improvements from baseline compared with PBO in mean HAQ-S (P=.007) and SF-36 PCS (P<.001) scores, and in 3 of 4 WPAI domain scores (P=.017, 0.041, 0.128, and 0.005, for absenteeism, presenteeism, overall work impairment, and activity impairment, respectively). By Week 52, PBO patients who switched to open-label ADA demonstrated improvements comparable to those in patients who received ADA during the double-blind period. Patients in both groups achieved SF-36 scores (43.2 and 44.3 for the PBO/ADA and ADA/ADA groups, respectively) approaching the US general population norm of 50 at Week 52.

Conclusion: Among patients with elevated CRP or positive MRI, ADA therapy was associated with significant improvement in PROs and productivity compared with PBO during the double-blind phase of the ABILITY-1 trial. Patients who continued on ADA therapy and those who switched to ADA in the open-label period experienced comparable meaningful improvements in PROs and productivity through Week 52.


Disclosure:

D. M. van Der Heijde,

AbbVie,

5,

Amgen,

5,

Aventis Pharmaceuticals,

5,

Bristol-Myers Squibb,

5,

Centocor, Inc.,

5,

Pfizer Inc,

5,

Roche Pharmaceuticals,

5,

Schering-Plough,

5,

UCB,

5,

Wyeth Pharmaceuticals,

5;

P. J. Mease,

AbbVie, Amgen, BiogenIdec, BMS, Celgene, Crescendo, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB, Vertex,

2,

AbbVie, Amgen, BiogenIdec, BMS, Celgene, Crescendo, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB, Vertex,

5,

AbbVie, Amgen, BiogenIdec, BMS, Crescendo, Genentech, Janssen, Lilly, Pfizer, UCB,

8;

A. L. Pangan,

AbbVie,

1,

AbbVie,

3;

S. A. Rao,

AbbVie,

1,

AbbVie,

3;

N. Chen,

AbbVie,

3,

AbbVie,

1;

M. Cifaldi,

AbbVie,

3,

AbbVie,

1.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/improvement-in-physical-function-health-related-quality-of-life-and-work-productivity-with-adalimumab-treatment-in-non-radiographic-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology